Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. méd. Chile ; 133(1): 71-76, ene. 2005. tab
Article Dans Espagnol | LILACS | ID: lil-398018

Résumé

Background: An important loss of bone mineral density, associated to pain and fractures, has been reported in children with acute lymphoblastic leukemia (ALL). Aim: To measure bone mineral density among children with acute lymphoblastic leykemia (ALL) that completed the remission induction phase with chemotherapy, that lasts 30 days. Patients and methods: children with ALL, admitted to the oncology unit of a general hospital were considered eligible for the study. body composition and bone mineral density were measured by dual energy x ray absorptiometry (DEXA). each child with ALL was paired with a healthly control. Results: Fourteen children age 1 to 11 years, completed the study, Spine and femoral bone mineral desities were significantly lower than in their matched controls. No differences in total body bone mineral density or content were observed. Children with ALL had a lower fat free mass and a higher fat mass than their matched controls. There was a significant correlation between fat free mass and bone mineral content. Conclusions: After one month of chemotherapy, children with ALL had a lower bone mineral density in the spine and femur and a lower fat free mass.


Sujets)
Mâle , Humains , Femelle , Nourrisson , Enfant d'âge préscolaire , Enfant , Densité osseuse , Leucémie-lymphome lymphoblastique à précurseurs B et T/physiopathologie , Leucémie-lymphome lymphoblastique à précurseurs B et T/traitement médicamenteux , Absorptiométrie photonique , Études transversales , Études cas-témoins , Facteurs temps
2.
Rev. chil. obstet. ginecol ; 70(5): 340-345, 2005.
Article Dans Espagnol | LILACS | ID: lil-449848

Résumé

El objetivo de este documento es entregar una guía práctica de tratamiento del climaterio, debido a la confusión producida por el estudio WHI en 2002. La TH debe ser solo utilizada cuando exista una indicación clara para su uso. La paciente sintomática es la principal beneficiada del tratamiento. No existe un tratamiento alternativo a los estrógenos o estrógeno/progestina tan eficaz en el alivio de la sintomatología y en reducción de fracturas. La indicación de un tratamiento prolongado debe ser revisada anualmente.


Sujets)
Humains , Femelle , Ménopause , Hormonothérapie substitutive/effets indésirables , Hormonothérapie substitutive/normes , Climatère , Oestrogènes/administration et posologie , Guides de bonnes pratiques cliniques comme sujet , Progestines/administration et posologie , Chlorhydrate de raloxifène/administration et posologie , Hormonothérapie substitutive
SÉLECTION CITATIONS
Détails de la recherche